Compare OneSpan Inc (OSPN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? OneSpan Inc trades at $17.52 (market cap $670.71M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 11.2× OneSpan Inc's market cap, and OneSpan Inc pays a 2.86% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| OSPN | SYRE | |
|---|---|---|
Market Cap | $670.71M | $7.52B |
Volume | 364,626 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $18.42 | $108.92 |
52-Week Low | $10.15 | $22.18 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $639.79M | $6.52B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $18.20, up 1.96% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with a 73.58% gross margin and consistent earnings beats, though net cash flow turned negative in 2026. Recent product innovation with DigipassONE and positive analyst coverage support the current valuation.
The outlook remains positive given strong profitability metrics and analyst consensus, but investors should monitor cash flow trends and competitive pressures in the cybersecurity sector. The stock's current valuation appears reasonable with a P/E of 10.28, offering potential upside if execution continues.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
